35 results about "Neuregulin" patented technology

To provide a method of treating a patient with chronic heart failure using a medicament comprising neuregulin.SOLUTION: A companion diagnostic test is first performed on each patient prior to treatment, and the appropriate treatment is provided to each patient according to the companion diagnostic test results. If the test results are within a preferred therapeutic range for treatment, the patient is suitable for treatment of heart failure by administration of an effective amount of neuregulin.SELECTED DRAWING: None

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

A method of treating or decreasing the risk of developing a respiratory viral infection in a subject is described. The method includes administering a therapeutically effective amount of neuregulin to the subject. A method of decreasing the risk that a subject will develop post-viral airway disease by administering an effective amount of neuregulin to the subject is also described.

The present application relates to the technical field of neuregulin 4 detection, and specifically to NRG4 detection primers, crRNA, CRISPR compositions, kits, and applications. The primer pair matches the target sequence of neuregulin 4. The NRG4 detection primers, crRNA, CRISPR compositions, kits, and applications provided in the embodiments can rapidly amplify the specific sequence of NRG4, and the amplified product can be targeted and cleaved by the CRISPR composition with high cleavage efficiency, and the cleavage product can greatly enhance the detection sensitivity.

The present application relates to a culture medium for the culture of intestinal organoids characterized in that it comprises neuregulin 1 (NRG1) and all-trans retinoic acid (atRA). It also relates to a method using this medium to culture intestinal organoids.

The present invention relates to doses and dosing regimens of an NRG4 compound in the treatment of cardiovascular disease (CVD) related conditions, including heart failure (HF).

To provide a method and a composition for preventing, treating or delaying myocardial injury in mammals.SOLUTION: Provided are an administration method for, an administration frequency of and an administration dosage of a pharmaceutical formulation or composition for reducing myocardial damage, using neuregulin. It can be proved in a rat myocardial damage model that neuregulin can improve the cardiac function after myocardial infarction, suggesting that neuregulin can be used for preventing, treating or delaying myocardial infarction damage.SELECTED DRAWING: None

Provided herein are methods and compositions for treating cancer, particularly the methods and compositions comprising a neuregulin 4 (NRG4) polypeptide.

The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

The invention relates to the technical field of organoid construction and culture, and discloses a yolk sac tumor organoid culture medium and application thereof. The culture medium comprises a basic culture medium and specific addition factors, and the specific addition factors comprise L-glutamine, a TGF-BI type receptor inhibitor A83-01, nicotinamide, an N2 supplement, a vitamin A-removed B27 supplement, N-acetylcysteine, beta-estradiol, a P38MAPK inhibitor SB202190, a bone morphogenetic protein antagonist Noggin, a Wnt pathway related protein R-Spondin-1, an epidermal growth factor, an insulin-like growth factor 1, an insulin-like growth factor 2, an insulin-like growth factor 3, an insulin-like growth factor 4, an insulin-like growth factor 5 and an insulin-like growth factor 6. The medicine composition is prepared from a liver cell growth factor, a neuroregulatory protein-1, a ROCK inhibitor Y27632, activin A and interleukin-6. By adopting the culture medium disclosed by the invention, the successful construction of the egg cystic tumor organoid can be realized, and the stable passage of the egg and the stable and rapid growth after passage can be realized.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Cardiac Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the heart. Also disclosed are subsequent generations of this Cardiac Targeting Peptide with improved, higher efficiency of cardiac uptake for CTP-mediated delivery of antiarrhythmics subjects for treating Atrial fibrillation or Ventricular fibrillation, CTP-mediated delivery of neuregulin-1β for treating systolic heart failure (SHF), and Szeto-Schiller peptides for treatment of diastolic congestive heart failure, among other applications.

Disclosed are pharmaceutical compositions comprising the growth factor neuregulin 1 (NRG1). Further disclosed herein are methods of using neuregulin 1, or pharmaceutical compositions comprising NRG1, to treat or prevent neurotrophic keratitis, methods to induce corneal headlining in an eye of a subject that has been denervated, and methods or preventing death of Schwann cells in the cornea of a subject that has suffered a corneal denervation.

The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein Neuregulin-1 (NRG-1) fused to a HER3 monoclonal antibody (mAb) backbone, and a method for treating atrial fibrillation and / or cardiac fibrosis in a subject in need of such treatment comprising administering a therapeutically effective amount of the recombinant fusion protein disclosed herein or a pharmaceutical composition comprising said recombinant fusion protein.

A culture medium for hepatoma organoid culture, comprising an MST1 / 2 kinase inhibitor, at least one cell culture additive selected from N2 and B27, a hepatocyte growth factor, an ITS cell culture additive, Y27632, dexamethasone, Neuregulin-1, insulin, an epidermal cell growth factor, GlutaMAX, and non-essential amino acids. The application further relates to a hepatoma organoid culture method and an application thereof. By using the culture medium for hepatoma organoid, effective and rapid expansion of the hepatoma organoid can be achieved, and the organoid obtained by such expansion maintains the pathological characteristics of a patient, improves the culture success rate and the expansion rate of the hepatoma organoid, and provides a research basis for individualized treatment of the patient.

This invention provides the application of neuregulin protein in the manufacture of drugs for preventing, treating, or delaying human heart failure, and methods for using such drugs. [Solution] The method includes: first examining the patient before treatment, wherein the examination includes detecting plasma levels of NT-proBNP or BNP; and subsequently providing appropriate treatment based on the examination results. If the examination results are within the optimal therapeutic range, the patient is suitable for treatment of heart failure by administering an effective dose of Neureglin.

The present invention provides a culture medium for primary intestinal cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; insulin; a Rho protein kinase inhibitor selected from at least one of Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; a glutamine additive; neuregulin 1; a bovine pituitary extract; basic fibroblast growth factor; R-spondin 1; prostaglandin E2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher amplification efficiency. Using this culture medium for primary intestinal cancer cells can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary intestinal cancer cell culture.

The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-I) fused to a HER3 monoclonal antibody (mAb) backbone and to a method of treating atrial fibrillation and / or cardiac fibrosis in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.

The present invention provides a culture medium and a culture method for intestinal cancer organoids. The culture medium comprises an MST1 / 2 kinase inhibitor; a B27 additive; an N2 additive; insulin; A8301; human fibroblast growth factor-10; neuregulin-1; amphiregulin; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; fetal bovine serum; basic fibroblast growth factor; insulin-like growth factor-1; forsklin; bovine pituitary extract; and fibroblast growth factor 7. Compared with existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Cultivating intestinal cancer organoids using this culture medium can maintain the morphological structure and pathological characteristics of the original tissue, thereby improving the success rate and survival rate of intestinal cancer organoid culture.

The invention discloses a culture medium of a breast cancer organoid, a culture method of the culture medium and application of the culture medium in drug detection, and relates to the technical field of cell and organoid culture, the culture medium of the breast cancer organoid comprises a basic culture medium and culture medium additives, and the culture medium additives comprise B-27, Neuregulin-1, Primocin, Y-27632 didrochloride, EGF, A83-01, N-Acetylcysteine and Nicotinamide; a method for culturing the breast cancer organoid by using the culture medium for the breast cancer organoid; the culture medium of the breast cancer organoid is applied to drug detection; by adopting the culture medium provided by the invention to culture the breast cancer organoid, the culture success rate and proliferation rate of the breast cancer organoid in the in-vitro culture process are improved, and the culture and drug detection period of the breast cancer organoid is shortened.

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

The present invention provides a pharmaceutical preparation for treating a cardiovascular disease. Particularly, the present invention provides a formula of a neuregulin pharmaceutical preparation. The formula consist of neuregulin polypeptide, a buffer, a stabilizer, an excipient, a salt, and another component, can ensure the long-term stability of the neuregulin polypeptide, and can be used for treating a heart failure patient or a patient in a risk of the heart failure.

The present invention relates to the dosage and administration regimen of NRG4 compounds in the treatment of cardiovascular disease (CVD)-related conditions including heart failure (HF).

The present invention relates to neuregulin positively dependent anti-human-HER3 antibodies comprising (i) a heavy chain wherein the variable domain has at least 90% or 95% identity with the amino acid sequence set forth as SEQ ID NO: 1 and (ii) a light chain wherein the variable domain has at least 90% or 95% identity with the amino acid sequence set forth as SEQ ID NO: 2. An immunoconjugate comprising an antibody of the invention or a fragment thereof, a nucleic acid sequence encoding an antibody of the invention or a fragment thereof, a vector as well as a host cell, a pharmaceutical composition comprising it, as well as their pharmaceutical use, are also considered.

The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.

This invention relates to liquid biopsy assays for the detection of neuregulin-1 (NRG1) fusion polynucleotides, particularly their use for diagnosing or treating disease, such as cancer. Novel neuregulin-1 (NRG1) fusion polynucleotides are also disclosed, as are kits for determining the presence or absence of an NRG1 fusion polynucleotide in a liquid biopsy sample. Methods of treating disease, such as cancer, are also disclosed.

The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

The invention relates to the field of neurological rehabilitation medicine, and particularly discloses application of task-oriented training in promoting functional recovery after spinal cord injury (SCI). The invention is based on the discovery that task-oriented training (such as single globule grasping training) can activate an NRG1 / ErbB4 signaling pathway by up-regulating the phosphorylation level of neuro-regulatory protein-1 (NRG1) and a receptor ErbB4 of the NRG1, thereby promoting regenerative cortical spinal bundle (CST) axons and spinal motor neurons to form functional excitatory synapses and inducing the conversion of synaptic phenotypes to excitatory. The invention provides a treatment method including task-oriented training and a combined strategy for combined application of the treatment method and a treatment method for activating endogenous axon regeneration capacity (such as by inhibiting PTEN expression), the treatment method is used for improving upper limb movement dysfunction after spinal cord injury, particularly after neck injury, and a new scheme is provided for clinical treatment.

Enterically coated formulations of polypeptides are provided, which provides protection to the polypeptides in oral administration and preferably slow release of the polypeptides in vivo. The polypeptides are analogs of neuregulin-4 and exhibit one or more activities of neuregulin-4, including the ability to induce homodimerization of ErbB4 subunits, the specificity in inducing homodimerization of ErbB4 over heterodimerization of ErbB family subunits. A couple of polypeptides further possess stability against enzymatic degradation. The formulations can be used in subjects with an inflammatory condition in the gastrointestinal tract.

Described herein, inter alia, are compositions of HERS ligands comprising degradation-increasing moiety, and compositions and methods for treating diseases associated with HERS activity, including cancer, in a patient in need of such treatment using the same. Further disclosed methods of treating a disease associated with EGFR activity, HER2 activity, HER4 activity, c-MET activity, RISK activity, MEK activity, MARK activity, RAF activity, BRAF activity, AKT activity, RAS activity, KRAS activity, or neuregulin activity in a patient in need of such treatment.

The invention relates to rapid construction and application of a tissue-derived high-flux respiratory system organoid pathogen infection and drug screening model. The invention provides a kit or a composition for inducing formation of a single respiratory system organoid sphere. The kit or the composition comprises a matrigel-free culture medium containing the following components: (1) a BMP inhibitor, (2) a WNT agonist, (3) a ROCK inhibitor, (4) a TGF beta inhibitor, (5) a MAPK inhibitor, (6) a growth factor, (7) a neuregulin family protein and (8) one or more cell interaction promoters. The invention further provides a preparation method and application of the respiratory system organoid. The method provided by the invention can quickly construct the highly uniform and ciliary eversion respiratory tract type organ from the body tissue in a high-flux manner without relying on matrigel.